Brief: Shield Therapeutics To Assume Full Commercial Control Of ACCRUFeR In US
27/08/2026 16:27
BRIEF-Shield Therapeutics To Assume Full Commercial Control Of ACCRUFeR In US Aug 27 (Reuters) - Shield Therapeutics PLC STXS.L:
SHIELD THERAPEUTICS - TO ASSUME FULL COMMERCIAL CONTROL OF ACCRUFER IN US WITH CLOSING EXPECTED SEPT 30, 2026
SHIELD THERAPEUTICS PLC: HAS ENTERED INTO AGREEMENT WITH VIATRIS INC UNDER WHICH SHIELD WILL ASSUME FULL COMMERCIAL RESPONSIBILITY FOR ACCRUFER®
SHIELD THERAPEUTICS - NO UPFRONT PAYMENTS TO VIATRIS FOR DEAL
SHIELD THERAPEUTICS PLC: TRANSACTION WILL BE IMMEDIATELY ACCRETIVE
SHIELD THERAPEUTICS - DEAL ENHANCES SHIELD'S EXPECTATION OF OPERATING PROFITABILITY IN 2026
Source text: ID:nRSa4923Sa
Further company coverage: STXS.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shield Therapeutics
See all newsBrief: Shield Therapeutics To Assume Full Commercial Control Of ACCRUFeR In US
Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US
Shield Therapeutics - Interim results for the six months ended 30 Jun 26
Brief: Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO
Shield Therapeutics - Q2 and H1 2026 Trading Update